Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the pulse wave velocity and vascular
compliance measurements at the beginning and the end of the study while the participants are
taking either extended release tacrolimus tablets (known by brand name Envarsus XR®, and also
referred to as LCPT in this study) given once-daily each morning after transplantation or
immediate release tacrolimus capsules (also known by brand name Prograf® or abbreviation
IR-TAC in this study) that are administered twice-daily 12 hours apart after kidney
transplantation. Pulse wave velocity and vascular compliance measurements are two
non-invasive tests that are used to evaluate how well the blood vessels adapt to each
heartbeat. The secondary purpose is to look at the effectiveness and safety of LCPT given
once-daily compared to IR-TAC given twice-daily 12 hours apart after kidney transplantation.